

*Department of Surgical Oncology,  
Osaka City University Medical School*



1-4-3 Asahimachi, Abeno-ku, Osaka 545-8585  
PHONE; 06-6645-3838, FAX; 06-6646-6450

August 8, 2015

Dear Editor:

Please find enclosed the edited manuscript in Word format (file name: 20342-review.doc).

**Title:** Molecular Targets for the treatment of pancreatic cancer: clinical & experimental evidence

**Authors:** Tasuku Matsuoka and Masakazu Yahsiro

**Name of Journal:** *World Journal of Gastroenterology*

**ESPS Manuscript NO:**

The manuscript has been improved (highlighted in yellow) according to the suggestions of reviewers. We modified carefully our manuscript to avoid overlapping.  
1 Format has been updated

2 Revision has been made according to the suggestions of the reviewer

(1) 186066

In this manuscript, the authors have summarised the clinical and experimental studied on molecular targeted therapies for pancreatic cancer.

This is a well written comprehensive summary.

I would suggest that the authors add a small description in the introduction on the different cell types involved in pancreatic cancer, i.e. cancer cell, stellate cells, cancer stem cells, stroma etc., their role in oncogenesis and also why conventional new drugs do not seem to act despite efficiency in cell lines/animal models (effect of cancer stroma).

*Response: Thank you for the reviewer's comment. We appreciate the reviewer's comments. As the reviewer mentioned, we have added sentences in the "introduction".*

In the section on experimental therapies, stick to cell lines and animal models. There in

one reference on a clinical study. This should be described in the section on clinical trials. Also mention names of the cancer cell lines and their types, ie. primary or metastatic, in the experimental study section.

*Response: Thank you for the kind suggestions. We have modified Table 1 by adding full study design and duration of treatment by referring the Clinical Trials. gov as possible We also add cell lines and their types used in the experimental study.*

Give a short description of triptolide. Give the full form of PR and DCR in the text.  
*Response: We apologize for the careless mistakes. According to your comments, We have mentioned a description of triptolide and full form of PR and DCR in the text.*

We modified carefully our manuscript according to Editor' comments.

1. Authors emphasis on oncologic benefit of Erlotinib should be balanced with potential complication.

*Response: Thank you for the kind suggestions. We have added sentence (Page 12 line 11-12) as Editor recommended.*

2. Following recent references may be helpful for the readers.

*Response: We added recent references as far as we searched.*

Thank you again for publishing our manuscript in the *World Journal of Gastroenterology*

Sincerely yours

Masakazu yashiro

Masakazu Yashiro, MD, PhD

Department of Surgical Oncology, Osaka City University Graduate School of Medicine,  
1-4-3 Asahi-machi, Abeno-ku, Osaka 545-8585, Japan

TEL; (+81) 6-6645-3838

FAX; (+81) 6-6646-6450

e-mail address; m9312510@med.osaka-cu.ac.jp

